Sutro Biopharma Inc (STRO) has a current Price-to-Book (P/B) ratio of -1.07. Compared to its 3-year average P/B ratio of 0.92, the current P/B ratio is approximately -215.94% higher. Relative to its 5-year average P/B ratio of 1.42, the current P/B ratio is about -175.15% higher. Sutro Biopharma Inc (STRO) has a Forward Free Cash Flow (FCF) yield of approximately -241.09%. Compared to its 3-year average FCF yield of -116.47%, the current FCF yield is approximately 107.00% lower. Relative to its 5-year average FCF yield of -74.78%, the current FCF yield is about 222.41% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for STRO competitors is 6.34, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO.O) exhibits a P/S ratio of 2.94, which is -53.68% above the industry average. Given its robust revenue growth of 13.77%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of STRO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of STRO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is STRO currently overvalued or undervalued?

What is Sutro Biopharma Inc (STRO) fair value?

STRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Sutro Biopharma Inc (STRO) is between 14.75 to 91.23 according to relative valuation method.

How does STRO's valuation metrics compare to the industry average?

The average P/S ratio for STRO's competitors is 6.34, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO) exhibits a P/S ratio of 2.94, which is -53.68% above the industry average. Given its robust revenue growth of 13.77%, this premium appears unsustainable.

What is the current P/B ratio for Sutro Biopharma Inc (STRO) as of Mar 03 2026?

As of Mar 03 2026, Sutro Biopharma Inc (STRO) has a P/B ratio of -1.07. This indicates that the market values STRO at -1.07 times its book value.

What is the current FCF Yield for Sutro Biopharma Inc (STRO) as of Mar 03 2026?

As of Mar 03 2026, Sutro Biopharma Inc (STRO) has a FCF Yield of -241.09%. This means that for every dollar of Sutro Biopharma Inc's market capitalization, the company generates -241.09 cents in free cash flow.

What is the current Forward P/E ratio for Sutro Biopharma Inc (STRO) as of Mar 03 2026?

As of Mar 03 2026, Sutro Biopharma Inc (STRO) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Sutro Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sutro Biopharma Inc (STRO) as of Mar 03 2026?

As of Mar 03 2026, Sutro Biopharma Inc (STRO) has a Forward P/S ratio of 2.94. This means the market is valuing STRO at $2.94 for every dollar of expected revenue over the next 12 months.

STRO Valuation